ArticleCureus2026
Anti-SSA/Ro60kd Antibodies Are Associated With Positive Salivary Gland Biopsy in Sjögren's Syndrome: A Retrospective Exploratory Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesSjögren's syndrome (SS) is a systemic autoimmune disease with heterogeneous clinical, laboratory, and histopathological manifestations, which complicate timely diagnosis. Minor salivary gland biopsy (MSGB) is a key component of SS classification, although its relationship with clinical and serological features remains incompletely characterized. This study aimed to evaluate the association between MSGB findings and clinical-laboratory variables in patients with SS and to identify variables associated with a positive biopsy.
methodsWe conducted a retrospective observational study at Braga Local Health Unit, including 37 patients diagnosed with SS between 1995 and 2024 who underwent MSGB. Patients were categorized into group A (positive biopsy, n = 17) or group B (negative biopsy, n = 20). Clinical, serological, and histopathological variables were analyzed using Fisher's exact test and multivariate logistic regression.
resultsThirty-seven patients were included (17 biopsy-positive, 20 biopsy-negative). The most frequent manifestations were ocular dryness (91.9%), oral dryness (78.4%), anti-SSA antibodies (Ro52: 51.4%; Ro60 kDa: 54.1%), antinuclear antibodies (ANA) titers >1:160 (64.9%), rheumatoid factor (RF) positivity (40.5%), elevated erythrocyte sedimentation rate (ESR) (67.6%), and arthralgia (56.8%). Fisher's exact test identified several statistically significant associations between clinical and serological variables. In multivariate logistic regression, anti-SSA Ro60 kDa positivity was independently associated with a positive biopsy result (OR: 12.94; 95% CI: 1.39-120.13; p = 0.024), while myalgias were associated with a lower likelihood of biopsy positivity.
conclusionThis exploratory study identified associations between serological markers and salivary gland biopsy findings in SS. Anti-SSA Ro60 kDa positivity may be associated with histopathological involvement; however, given the small sample size and wide confidence intervals, these findings should be interpreted cautiously and require validation in larger prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.